Recordati

Recordati
Name	Recordati
Type	Public
Industry	Pharmaceuticals
Founded	1926
Founder	Giovanni Recordati
Headquarters	Milan, Italy
Products	Pharmaceuticals, specialty medicines
Revenue	(see Financial performance)
Website	(omitted)

Recordati

Recordati is an Italian multinational pharmaceutical company headquartered in Milan, known for developing, manufacturing, and marketing prescription medicines and specialty products across Europe, the Americas, and Asia. The company operates within regulatory frameworks established by agencies such as the European Medicines Agency, U.S. Food and Drug Administration, and national authorities, and engages with partners including multinational firms and regional distributors. Recordati’s strategic activities intersect with institutions like the World Health Organization and industry associations such as the European Federation of Pharmaceutical Industries and Associations while participating in research networks involving universities and contract research organizations.

History

Founded in 1926 by Giovanni Recordati, the company expanded from a regional pharmaceutical distributor into an international group through organic growth and acquisitions. Throughout the 20th century Recordati interacted with events and entities such as post-war reconstruction in Italy, industrial modernization policies by the European Economic Community, and regulatory evolutions led by the Ministry of Health (Italy). The group pursued market entry strategies into countries including France, Spain, and Portugal during the late 20th century, and later expanded into the United States, Canada, and Latin American markets through strategic deals and the acquisition of portfolios from multinational corporations like Sanofi and other industry players. Recordati’s timeline includes listing milestones on the Borsa Italiana and corporate milestones involving family governance and succession common among European pharmaceutical houses.

Business operations

Recordati’s operations span research and development, manufacturing, regulatory affairs, marketing, and distribution. The company manages manufacturing sites and subsidiaries across jurisdictions such as France, Germany, United Kingdom, United States, Brazil, and Japan, coordinating with contract manufacturing organizations and logistics providers. Commercial activities involve collaborations with wholesalers, hospital procurement systems, and specialist prescribers in therapeutic areas regulated by authorities including the National Health Service (England) and regional procurement agencies. Recordati has engaged in licensing agreements, strategic alliances, and out-licensing with companies like Pfizer, Bristol Myers Squibb, and regional partners to optimize market access and lifecycle management of products.

Products and research

Recordati’s product portfolio emphasizes specialty medicines across therapeutic areas such as cardiology, urology, endocrinology, and rare diseases. The company’s pipeline development has involved clinical programs conducted in accordance with guidelines from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and trial registration with regulators like the European Medicines Agency and the U.S. Food and Drug Administration. Recordati has acquired and developed brands and registered medicines through transactions with firms such as AstraZeneca and Eli Lilly, and collaborates with academic institutions and research hospitals including University of Milan and major clinical research networks for investigator-initiated and company-sponsored studies. In rare disease research, Recordati participates in orphan drug designations and interacts with patient organizations and registries, aligning with policies from the European Commission and incentive frameworks such as the Orphan Drug Act (United States).

Corporate governance and ownership

Recordati’s governance structure reflects a publicly listed company with a board of directors, executive management, and significant family ownership typical of long-established European companies. The firm’s shares trade on the Borsa Italiana where institutional investors such as asset managers and pension funds, and family-controlled holdings, influence strategic decisions. Governance mechanisms include audit committees, remuneration committees, and compliance frameworks that reference standards set by market regulators like the CONSOB and corporate governance codes promoted by the Italian Corporate Governance Committee. Recordati’s ownership history features family stewardship, succession events, and periodic engagement with activist investors and proxy advisory services in the context of shareholder votes and strategic transactions.

Financial performance

Recordati’s financial results reflect revenue streams from product sales, licensing income, and milestone payments tied to collaborations and divestments. The company reports consolidated income and balance sheet items in line with accounting standards used in Italy and the European Union, interacting with auditors and financial intermediaries. Revenue growth has been influenced by acquisitions, product launches, and geographic expansion into markets such as Russia (subject to geopolitical considerations), Mexico, and Turkey, while cost structures are affected by R&D investment, manufacturing expenses, and regulatory compliance. Capital market activities include equity and debt financing engagements with banks and capital markets, as well as dividends and reinvestment decisions that attract coverage from sell-side analysts and rating agencies.

Corporate social responsibility and controversies

Recordati engages in corporate social responsibility initiatives involving patient support programs, philanthropic partnerships with foundations, and participation in public health initiatives alongside organizations such as the World Health Organization and local health ministries. The company’s ethical and compliance programs reference codes from industry associations like the European Federation of Pharmaceutical Industries and Associations and anti-corruption standards aligned with OECD guidance. Like many multinational pharmaceutical firms, Recordati has faced scrutiny over pricing, marketing practices, and patent litigation involving competitors and generic manufacturers in jurisdictions governed by courts and patent offices such as the European Patent Office and national judicial systems. The company responds through legal proceedings, public disclosures to market authorities, and adjustments to commercial strategies in response to stakeholder concerns.

Category:Pharmaceutical companies of Italy